Top 12 AI Stock News and Ratings Dominating Wall Street

Page 2 of 11

10. Tempus AI, Inc (NASDAQ:TEM)

Number of Hedge Fund Holders: 7

Tempus AI, Inc (NASDAQ:TEM) is a healthcare technology company that provides AI-enabled precision medicine solutions. On December 16, the company announced that it has expanded its relationship with Personalis, Inc. (NASDAQ:PSNL), a provider of advanced genomic sequencing and analytics solutions. The companies had initially collaborated in November 2023 to bring ultra-sensitive MRD testing to market, a testing procedure used to check if a cancer treatment is working.

They launched their efforts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Tempus serves as the exclusive commercial diagnostic partner for Personalis’ ultra-sensitive tumor-informed MRD product, NeXT Personal® Dx. This product focuses on breast and lung cancers as well as immunotherapy for solid tumors. Strong market interest has led the companies to expand their relationship, where Tempus will offer Personalis’ MRD product to pharmaceutical and biotech companies.

While we already offer NeXT Personal through our own biopharma channel, we are pleased to leverage Tempus’ integrated platform as well for these biopharma customers who desire to combine NeXT Personal with other Tempus products. We believe the expansion of the relationship with Tempus will accelerate market penetration of our leading ultra-sensitive MRD platform and allow us to better capitalize on the opportunity”.

-Chris Hall, CEO of Personalis.

Page 2 of 11